A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-30

Study Completion Date

2024-07-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1 study which consists of 2 parts; Dose Escalation part and Expansion part.

The dose escalation part is open-label, and evaluates safety, preliminary efficacy and PK of single-agent talazoparib in sequential cohorts of adult patients with advanced solid tumors who are resistant to standard therapy or for whom no standard therapy is available.

In the dose escalation part, up to 18 (minimum 3) patients are expected to be enrolled depending on the observed DLTs.

The expansion part is designed to assess the efficacy, safety and PK of single-agent talazoparib at RP2D determined in the dose escalation part in adult patients with locally advanced or metastatic breast cancer who have deleterious or suspected deleterious germline BRCA1 or BRCA2 mutations.

In the expansion part, a minimum of 17 patients will be enrolled evaluable for the primary endpoint.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors

NCT03497429

Advanced Solid Tumors

COMPLETED PHASE1

STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS

NCT04635631

Neoplasms

COMPLETED PHASE1

A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors

NCT01610479

Advanced Solid Tumors

COMPLETED PHASE1

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

NCT05070247

Pancreatic Cancer Hepatocellular Cancer Mesothelioma +7 more

TERMINATED PHASE1/PHASE2

A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors

NCT07077434

Advanced Solid Tumors

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms Breast Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

talazoparib

0.75 mg/day or 1.0 mg/day

Group Type EXPERIMENTAL

talazoparib

Intervention Type DRUG

Talazoparib will be administered orally on a continuous basis. Talazoparib may be taken with or without food. Each cycle will consist of 28 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

talazoparib

Talazoparib will be administered orally on a continuous basis. Talazoparib may be taken with or without food. Each cycle will consist of 28 days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histological or cytological diagnosis of locally advanced or metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
* ECOG Performance Status 0 or 1.
* Adequate Bone Marrow, Renal and Liver Function.

* Histologically or cytologically confirmed carcinoma of the breast.
* Locally advanced breast cancer that is not amenable to curative radiation or surgery and/or metastatic disease.
* Documentation of a deleterious, suspected deleterious, or pathogenic germline BRCA1 or BRCA2 mutation by Myriad Genetics' BRACAnalysis CDx test.
* No more than 3 prior chemotherapy-inclusive regimens for locally advanced or metastatic disease.
* Have measurable lesion by the RECIST v.1.1.
* ECOG Performance Status 0-2.
* Adequate Bone Marrow, Renal and Liver Function.

Exclusion Criteria

* Patients with known symptomatic brain metastases requiring steroids.
* Current use of a strong P-gp inhibitor, strong P-gp inducer, or strong inhibitor of BCRP within 1 week or 5 half lives which ever is longer prior to the first dose of study treatment.
* Fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception.

\[Dose Expansion Part\]

* First-line locally advanced or metastatic breast cancer with no prior neoadjuvant and adjuvant chemotherapy.
* Prior treatment with a PARP inhibitor.
* Objective disease progression while receiving platinum chemotherapy administered for locally advanced or metastatic disease.
* HER2 positive breast cancer.
* Active inflammatory breast cancer.
* Central nervous system (CNS) metastases.
* Current or anticipated use within 7 days prior to the first dose of study treatment, or anticipated use during the study of strong P-gp inhibitors.
* Fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No